The Development and Validation of the Successful Psychopathy Scale [Protocol]

Louise Wallace,¹,⁴ *, Oleg Medvedev, PhD³,⁵, Dean Fido, PhD²,⁶, Alexander L. Sumich, PhD¹,⁷, Nadja Heym, PhD¹,⁸

Abstract
The personality construct known as ‘Successful Psychopathy’ has attracted the interests of researchers and clinicians alike. The concept suggests an individual who demonstrates the core traits associated with psychopathy but is able to adapt and function within society to prototypical or superior standards. There has yet to be a sound theoretical model of this construct by which to base a psychometric measure. This protocol presents the ethical procedure that will endeavour to create such a measure and validate it within general population samples.

Keywords: Psychopathy, Successful Psychopathy, Scale Development

¹ Nottingham Trent University, 50 Shakespeare Street, Nottingham, NG1 4FQ, UK
⁲ University of Derby, Kedleston Road, Derby, DE22 1GB, UK
³ University of Waikato, Hillcrest, Hamilton 3216, New Zealand
⁴ ORCiD: https://orcid.org/0000-0003-2706-4373
⁵ ORCiD: https://orcid.org/0000-0002-2167-5002
⁶ ORCiD: https://orcid.org/0000-0001-8454-3042
⁷ ORCiD: https://orcid.org/0000-0003-4333-8442
⁸ ORCiD: https://orcid.org/0000-0003-2414-8854

*Corresponding author: Louise Wallace, louise.wallace@ntu.ac.uk
Purpose

The primary objective of this investigation is to develop the first Successful Psychopathy psychometric measure and to validate it within a cohort derived from the United Kingdom (UK).

Background

A Successful Psychopath refers to an individual who demonstrates the core traits associated with psychopathy, whilst simultaneously being able to adapt within society with intact or superior levels of functioning (Lilienfeld, 2014). It has been speculated that such individuals would be able to gain status and resources with minimal effort needed (Babiak & Hare, 2006). In addition, these individuals would likely demonstrate certain traits which would better allow them to adapt and function successfully within society, some such traits could be resilience (Dutton, 2013), a bold interpersonal style (Hare, 1999), as well as reduced shame, guilt, and remorse (Lilienfeld & Windows, 2005). Whilst some of these traits are shared with prototypical psychopathy, they may also be prevalent in those who deviate from antisocial or criminal behaviour, similarly to one of the original conceptualisations of psychopathy derived by Hervey Cleckley (1951/2016) who suggested criminal or antisocial behaviour was not a likely outcome of the disorder, allowing these individuals to essentially fly under the radar (Widom, 1977). Moreover, these individuals could be able to apply these traits to gaining positions of leadership (Judge & LePine, 2007). At the time of writing, there is currently no psychometric measure equipped to identify and improve understanding of these individuals who appear to develop atypically across the psychopathy spectrum, this is partly due to the ongoing debate regarding the theoretical construct of Successful Psychopathy and lack of a measure suited to measuring these traits within general population samples. As such, in order to achieve our aims, we seek to develop and validate the first Successful Psychopathy measure and investigate its reliability and validity within general population samples with the UK. Moreover, as the construct has never been formally defined in this way, and psychopaths are estimated to make up around 1% of the general population (Hare, 1999), this study will also seek to investigate the relationship between the newly developed scale and existing measures of psychopathy, professional success, and life success, as well as theorise on potential prevalence of successful psychopathy, and provide a comprehensive understanding of a construct which is largely controversial and currently holds conflicting theoretical evidence which will be beneficial to the research community.

Objectives

1. Develop the Successful Psychopathy psychometric scale using Classical Test Theory (CTT) and Rasch Analysis
2. Validate the Successful Psychopathy Scale
3. Assess test-retest reliability of the Successful Psychopathy Scale
**Duration of studies**

Through the use of the participant crowdsourcing website Prolific (see ‘Recruitment Methods’), enrolment and data collection of this study is estimated to take around 7 months to complete, due to administering the measure across three occasions to determine test-retest reliability. However, enrolment of the initial collection will remain open until the minimum sample ($n = 400$) is met, with additional data collected if necessary. The minimum sample size required was based on previous scale development research within a similar field (Caring Uncaring Emotional inventory, Semel, 2016) and the minimum sample required to conduct CTT. The duration of this study for each participant is expected to be no longer than 15 minutes at each timepoint.

**Methods**

**Study Designs**

This cross-sectional study will initially involve 400 participants completing a battery of questionnaires at a single timepoint. Demographics (i.e., age & sex), the newly developed Successful Psychopathy Scale (which will include items developed based on theoretical understanding of the construct, formulated from previous literature including a systematic review (Wallace et al., 2019) and expert ratings), and state measures of psychopathy, political skill, and expectancy for success. Responses to the Successful Psychopathy Scale only will be taken at two additional timepoints (3-6 months). Responses will be measured online using survey software Qualtrics.

**Study Population, Selection Criteria, and Sample Size Justification**

All participants will provide full informed consent, as indicated by a button press on the first and final pages of the survey. Participants will be males and females aged 18 years and over, of UK nationality, and fluent in English.

Sample size was derived based upon minimum and optimum sample sizes required to undergo Classical Test Theory or Exploratory Factor Analysis (CTT; EFA) and Rasch Analysis (Linacre, 1994/99; Tabachnick & Fidell, 2013).

**Recruitment Methods**

Participants will be identified through the crowdsourcing website Prolific (prolific.co), and the study survey will be made available to all members who meet the required inclusion criteria. This is an automated process determined through member responses to a series of questions answered when first signing up the platform. Prolific is thought to generate data quality comparable to that obtained by face-to-face means (Peer et al., 2017). Members who go on to participate in the study will be paid an average of £5 per hour; roughly £0.85 for this study (10 minutes). At the
time of writing there are 33,469 potential participants to take part in this study, so data collection for this purpose is feasible.

**Data Collection and Study Schedule**

The initial survey will consist of the Successful Psychopathy Scale, plus a battery of questionnaires, which will be collected at one timepoint. On the first two pages of the survey, participants will be presented with all study information and will be asked to affirm their consent. On subsequent pages (not accessible unless consent has been given), participants will be asked to answer brief demographic questions (i.e., age, sex) prior to completing five psychometric measures, namely the Successful Psychopathy Scale (*in prep*; Wallace et al., 2020), the 58-item Triarchic Psychopathy Measure (TriPM; Patrick et al., 2010), the 30-item Generalised Expectancy for Success Scale (GESS; Fibel & Hale, 1978), the 42-item Life Success Measures Scale (LSMS; Parker & Chusmir, 1992), and the Political Skills Inventory (PSI; Ferris et al., 2005). Each scale will be presented, along with completion instructions, on a separate page, and the study will close with a debrief page where participants will be asked to re-affirm their consent. Two additional timepoints will be collected for the Successful Psychopathy Scale at 3- and 6-month intervals. Data will be maintained for as long as necessary (with identifiable data destroyed after two weeks from each timepoint) for the purpose of transparent and open science, with the exception of data obtained from participants who withdraw from the study either during or following participation (up to a period of two weeks). In such cases, any associated data will be permanently deleted.

**Expected Outcomes**

The research team expects the Successful Psychopathy Scale to hold a similar theoretical structure to the initial conceptualisation of psychopathy as derived by Cleckley (1955/2016). Moreover, as existing literature suggests, it is expected that the Successful Psychopathy Scale will be positively associated with self-reported boldness (Persson & Lilienfeld, 2019), meanness (Persson & Lilienfeld, 2019), political skill (Lilienfeld et al., 2012). Furthermore, it is theorised that successful psychopathy will be positively associated with an expectancy of success within professional domains (e.g., status and wealth) and be negatively associated with disinhibition and expectancy of success in personal domains (e.g., family).

**Ethical considerations**

Participants will provide consent and will be debriefed following the study. There is no expectation of any adverse outcomes or effects on participants as a direct result of this study. Nevertheless, the research team acknowledges that questions asked within this study relate to personality, which may lead participants to ruminate on their wellbeing. As such, participants will be signposted to UK-based mental health charities (e.g., MIND) and their healthcare providers (e.g., general practitioners) at both
the point of consent and the debrief. Participants are neither asked nor expected to disclose any subsequent correspondence with such services to the research team.

Withdrawals

Reasons for Withdrawal

Potential participants identified via Prolific are under no obligation to take part in the study. Participants who do consent to take part can withdraw their consent either during the study (by closing their web browser or by not affirming consent at the point of debrief) or after taking part in the study up to two weeks prior (by e-mailing the Principal Investigator (PI) using the provided e-mail address with their Prolific ID, an ID associated with their specific data entry). No reason for this withdrawal will be asked or expected to be given. Participation in the study may be automatically terminated (via Qualtrics settings) should the participant decline to give consent. No adverse events will be measurable during the study due to the data being collected remotely and not in person. As such, no considerations are made for adverse events that lead to participant termination up to two weeks following participation.

Handling of Participant Withdrawal

As mentioned above, participants may withdraw at any time during the study and up to two weeks afterwards, and participants will not be asked to give a reason for their withdrawal. Participants who withdraw from the study will be replaced, and in such instances, further participants will be sampled to ensure the study sample does not fall under the optimal number.

Premature Termination or Suspension of Study

Although not expected, the study may be temporarily suspended or prematurely terminated if there is sufficient and reasonable cause to do so. In such instances, the PI will directly notify the research ethics committee that approved the study in writing, providing reason(s) for the suspension and/or termination of the study. Potential circumstances which might result in temporary suspension or premature termination include [1] unexpected, significant, or unacceptable risk to participants, [2] determination of futility, and [3] unexpected detriment to the secure maintenance and quality of data. The study may resume once any concerns have been addressed and satisfy the needs of both the research team and research ethics committee.

Statistical Analysis Plan

All analyses for this study have been determined a priori. To determine the construct validity of the newly developed Successful Psychopathy Scale, exploratory factor analyses (CTT; EFA) will be run on the complete data set to determine the component structure. Once a sound theoretical model has been found, this will then undergo Rasch Analysis. Rasch Analysis has been shown to overcome some of the limitations often
found with CTT, for example using Differential Item Functioning (DIF) to determine non-consistent responses across a trait and identify candidates for removal from a scale. Additionally, Rasch allows precise measurements of individuals at the extremes of a scale (Hobart & Cano, 2009) which is particularly relevant when assessing Successful Psychopathy where the research team are interested in those extreme scores.

To determine concurrent and convergent validity of the scale Pearson’s correlations and linear regressions will be conducted between each variable.

**Assessment of Safety**

Although not expected, this study will follow standard definitions of adverse events (AEs) and report any AEs to the research ethics committee for up to two weeks after the final participant has taken part in the study.

**Adverse Events**

Defined as any unanticipated physical or mental well-being occurrence, regardless of its relationship to the study, such as self-reported stress or anxiety following participation in the study that may or may not require further intervention.

**Serious Adverse Events**

Defined as AEs that are considered serious, such as those requiring hospitalisation, are life-threatening, or result in death.

In the event of any AE being acknowledged by the research team, the PI will assign a level of severity to the event (Mild, Moderate, Severe) and assess the likelihood that said AE is related to the study protocols (Definitely, Probably, Possibly, Unrelated). These categories are further delineated in Table 1.

### Table 1.

**Severity and relationship of adverse event to study protocol**

<table>
<thead>
<tr>
<th>Label</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild</td>
<td>Requires no or minimal intervention; not impacting the participant</td>
</tr>
<tr>
<td>Moderate</td>
<td>Moderate inconvenience to the participant; potentially interfering with day-to-day activities of the participant</td>
</tr>
<tr>
<td>Severe</td>
<td>Severe inconvenience to the participant that may require intervention; severely interfering with day-to-day activities of the participant and may be life-threatening</td>
</tr>
<tr>
<td>Definitely</td>
<td>The relationship between the AE and the study protocol can be clearly established</td>
</tr>
</tbody>
</table>

The Journal of Concurrent Disorders, 2021
The relationship between the AE and the study protocol cannot be clearly established, however there is no other reason or event which could clearly explain the occurrence of the AE

<table>
<thead>
<tr>
<th>Probably</th>
<th>The relationship between the AE and the study protocol cannot be clearly established, however there is no other reason or event which could clearly explain the occurrence of the AE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Possibly</td>
<td>The relationship between the AE and the study protocol cannot be clearly established, but the definite lack of a relationship cannot be concluded</td>
</tr>
<tr>
<td>Unrelated</td>
<td>There is no relationship between the AE and the study protocol.</td>
</tr>
</tbody>
</table>

**Data Monitoring**

The PI will be responsible to ensure the study is conducted in accordance with the protocol, standards of Good Clinical Practice (GCP), and applicable regulatory requirements as defined by the British Psychological Society (BPS), and that the data recorded is valid and appropriately stored and maintained. To this end, data collection (via Prolific) will be collected in three stages to ensure quality: Stage 1 being a short pilot of five participants to check data quality and difficulties arising from the usability of the questionnaire, and Stages 2 and 3 being the collection of male and female responses separately to ensure a good distribution of data across sexes. The questionnaire pack is devised in a manner to minimise errors (e.g., clear instructions) and uses a ‘request response’ function in order to remind participants to complete all sections of the survey should any question be missed. To comply with ethical standards, although this function is enabled, participants will be able to subsequently skip said item should they not wish to complete it.

No external data monitor will be appointed to ensure the study complies with GCP or BPS standards. Data and analysis scripts will be made available on request.

**Data Handling and Record Keeping**

The collection of personal data from the participants will be limited to the number and type required to perform the planned analyses and in order to achieve the aims of the research. Data will be maintained on Qualtrics (survey software and secure database) until the required sample size has been collected, at which point the data will be exported into an Excel or SPSS file format (password protected), backed-up, and subsequently deleted from Qualtrics. Any unique identifiers collected within the dataset will be permanently deleted two weeks after the final participant completes the study, and there will be no hard copies of the data.
generated or maintained. Fully anonymised data will be used for data analysis, which will be led by the PI (LW).

**Research Ethics Committee**

The protocol, participant-facing documents, and questionnaire pack will be submitted to a local research ethics committee for review, feedback, and approval. Approval of all documents is required before any participant enters into the study. Any amendment to the protocol will undergo further review and approval by the research ethics committee before the changes are implemented to the study; however, as participation is anonymous and participants are not requested to provide contact details, re-consent to take part in the study will not be possible, and as such any data obtained prior to amendments will only be treated in accordance with the elements and procedures for which consent was given.

**Consent Process**

After clicking on the study link and being presented with the study information sheet (including all information about the study, methods of withdrawal, information about data management, and contact details of the study team and signposted services), participants will then be presented with the consent form on the subsequent page of the online survey. To take part in the study, participants must affirm their consent and understanding of the aforementioned information via a button press; refusal to do this will lead the Qualtrics software to terminate their participation with a ‘thank you’ message. Participants will also be shown an optional consent box for the test-retest follow ups at 3 and 6 months, this is not mandatory and selecting ‘I do not consent to take part in the follow-up survey’ will allow them to complete the initial questionnaire with no expectation to take part in any of the subsequent surveys. Participants will not have to sign, date, or present any additional identifiable information. Following a debrief of the study, and in accordance with guidelines for internet mediated research (BPS, 2017), participants will be asked to re-affirm their consent as a means of mitigating against the usage of data from participants who prematurely exited the study and/or those who no longer wish for their data to be used after completing the study.

**Protocol Deviation**

Protocol deviations are defined as any deviation from the ethically approved study protocol and can be attributed to either the research team or study participants. However, as the nature of the study makes it improbable that participants could generate protocol deviations, a research team-related example of a protocol deviation for this study might include the use and storage of data in an unapproved manner. Any protocol deviation will be
made aware to the research team at the earliest availability and corrective measures will be actioned if appropriate. Causes, actions, and results of any protocol deviations will be signalled to the research ethics committee in writing at the first available opportunity.

**Publication and Data Sharing Policy**

It is the intention of the research team to publish any and all findings of this study in written (e.g., posters, journal publications, blog posts) and verbal (e.g., conference paper) form. The research team might also use findings of this study as a base for future research submissions and/or grant applications. At all stages, individual participant responses and associating identifiable information will be kept confidential, and only group-level analyses will be presented/published. In accordance with emerging trends in open science, anonymised raw data and pre-print manuscripts will be made openly available.

**Study Personnel and Roles**

Table 2 documents the members of the research team and their associated responsibilities throughout the duration of the project.

Table 2.

*Outline of research team personnel and associated project roles*

<table>
<thead>
<tr>
<th>Personnel</th>
<th>Role</th>
<th>Responsibilities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Louise Wallace</td>
<td>Principal Investigator</td>
<td>Responsible for all study-related issues</td>
</tr>
<tr>
<td>Nadja Heym</td>
<td>Co-Investigator</td>
<td>Study design and final review</td>
</tr>
<tr>
<td>Oleg Medvedev</td>
<td>Co-Investigator</td>
<td>Data analysis, manuscript drafting, final review</td>
</tr>
<tr>
<td>Alexander Sumich</td>
<td>Co-Investigator</td>
<td>Final review</td>
</tr>
<tr>
<td>Dean Fido</td>
<td>Co-Investigator</td>
<td>Data collection and final review</td>
</tr>
</tbody>
</table>

**Funding**

This research was supported in part by an Early Career Researcher Grant from University of Derby.
Conflict of Interest
The authors declare no conflict of interest.

Ethics Approval
This project received ethical approval from Nottingham Trent University.

References